Replies to post #53406 on Biotech Values

[exwannabe]

RE: INGN

OK, after going through this in a lot more detail I do realise that this comapany is an absolute disaster.

On the last CC they focused on some other companies related drug trial halt, saying how great it was that INGN's Advixin wasn't effected, and totally glossed over the fact that the P3 top line data isn't out well after it should be (presumably that is, because they never actually stated when/if unblinding of the final data happened).

I am stunned that this stock trades over $1.